Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
190.66
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Danaher Revenue
In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%. Danaher had revenue of $6.54B in the quarter ending December 31, 2024, with 2.08% growth.
Revenue (ttm)
$23.88B
Revenue Growth
-0.06%
P/S Ratio
5.72
Revenue / Employee
$378,968
Employees
63,000
Market Cap
133.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
| Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
| Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
| Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
| Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
DHR News
- 17 days ago - 3 Wide-Moat Dividend Stars For A Championship Portfolio - Seeking Alpha
- 19 days ago - Danaher Corporation: A Mixed Bag Of Strength And Stagnation - Seeking Alpha
- 19 days ago - Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations - Seeking Alpha
- 25 days ago - 8 Upcoming Dividend Increases, Including A King - Seeking Alpha
- 4 weeks ago - Danaher: Near 5-Year Low Is A Great Entry Point - Seeking Alpha
- 4 weeks ago - Danaher Schedules First Quarter 2025 Earnings Conference Call - PRNewsWire
- 5 weeks ago - Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System - PRNewsWire
- 6 weeks ago - Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript - Seeking Alpha